Analysis
Oura, the smart-ring maker valued at $11 billion, has agreed to acquire Counsel Health, an AI-native primary care company, for $625 million in cash, subject to purchase price adjustments, the companies announced on November 10, 2026 in Counsel's release. The deal is expected to close before the end of the calendar year, subject to customary closing conditions.
Alongside the deal, Oura disclosed preliminary, unaudited revenue of $533 million for its fiscal fourth quarter ended September 30, 2026, up 153% year over year, and adjusted EBITDA of $87 million, a 16% margin.
What does Counsel Health do?
Counsel combines medical AI with in-house physicians and sells that service to health plans, health systems, digital health companies, employers and consumers, pitching it as a replacement for nurse triage lines and conventional telehealth, per the release. Counsel was founded in 2023, according to its seed announcement, and is led by founder and CEO Muthu Alagappan, MD. TechCrunch reported that Counsel's chat-based AI and licensed physicians have been available inside the Oura app since June, that its 70 employees are joining Oura per Bloomberg, and that Alagappan becomes Oura's chief clinical AI officer. Counsel says it will keep serving its existing enterprise partners. Among Counsel members surveyed, more than 90 percent said their Oura data helped them get better care, and members who saw a Counsel physician rated the experience 4.6 out of 5, per the release.
“Oura was founded in Finland in 2013 and is headquartered in San Francisco, with more than six million members, per the release.”
Value Add VC data: how much did Counsel Health raise?
Counsel's disclosed rounds and the exit, from the companies' releases and TechCrunch:
- Oct 2024, Seed -- $11M, valuation not disclosed, led by Andreessen Horowitz (a16z) Bio + Health, with Asymmetric Capital Partners, Floodgate Fund and Pear VC participating (PR Newswire)
- Oct 2025, Series A -- $25M, valuation not disclosed, led by Andreessen Horowitz and GV (TechCrunch)
- Nov 2026, acquisition -- $625M in cash by Oura (Counsel Health)
PitchBook estimates Counsel's total funding at $36 million, TechCrunch reported. No priced valuation for either round has been published, so we cannot state the purchase price as a multiple of a prior mark; what the numbers do show is a cash exit roughly two years after the seed round, on an estimated $36 million raised. Investor ownership and proceeds are undisclosed.
Oura revenue, valuation and the shelved IPO
Oura was founded in Finland in 2013 and is headquartered in San Francisco, with more than six million members, per the release. It expects fiscal 2026 revenue of about $1.75 billion, up 92%.
Pulse covered the postponed Oura IPO. The record, per Tech Funding News:
- Oura IPO, shelved Sept 29, 2026 -- postponed indefinitely, citing "uncertainty in the IPO market"; Oura had planned to raise up to $2.2 billion selling 50 million shares at $40 to $44, which would have valued it at up to $15 billion at the midpoint.
- Oura Series E, Oct 2025 -- $900 million led by Fidelity at an $11 billion valuation, its last private mark.
Smart ring market and competitors
The deal pushes Oura from tracking into treatment, where hardware rivals do not yet play. The comparable wearables numbers on record:
- Ultrahuman -- raised $70 million in September 2026, led by Qualcomm Ventures, at a $365 million valuation, as reported by Tech Funding News.
- Samsung Galaxy Ring -- the big-tech ring competitor named by Tech Funding News; no Samsung ring revenue is broken out.
- RingConn -- a lower-priced ring maker TechCrunch lists among Oura's rivals.
On the care side, Counsel's pitch is against nurse lines and telehealth visits, which places Oura in a market run by clinicians and payers rather than gadget makers.
Risks in the Counsel deal
The $625 million is a large cash commitment for a company that just pulled a $2.2 billion IPO, and it buys a 70-person clinical business that must keep its health plan and employer contracts while its owner becomes a consumer hardware company. Physician-led care also brings licensing, liability and reimbursement exposure that a ring maker has never carried. The deal is expected to close before year-end, per the release, and the price is still subject to adjustments. The next numbers to watch are Oura's audited fiscal 2026 results and any refiling for the IPO with Counsel's revenue inside it.